Laser therapy in oral mucositis control: a meta-analysis  by Peixoto Figueiredo, André Luiz et al.
2255-4823© 2013 Elsevier Editora Ltda. 
  
ASSOCIAÇÃO MÉDICA BRASILEIRA
REVISTA DA
7PMVNFt/ÞNFSPt/PWFNCSP%F[FNCSPt*44/t*44/	0OMJOF

www.ramb.org.br
ARTIGOS  
ARTIGOS ORIGINAIS _____________ Qualidade da informação da internet disponível para pacientes em páginas  
 em português ___________________________________________________________ 645
Acesso a informações de saúde na internet: uma questão de saúde pública? ______ 650
 Maus-tratos contra a criança e o adolescente no Estado de São Paulo, 2009_______ 659
 Obesidade e hipertensão arterial em escolares de Santa Cruz do Sul – RS, Brasil ___ 666
 Bone mineral density in postmenopausal women with and without breast cancer ___ 673
 Prevalence and factors associated with thoracic alterations in  
 infants born prematurely __________________________________________________ 679
 Análise espacial de óbitos por acidentes de trânsito, antes e após a Lei Seca,  
 nas microrregiões do estado de São Paulo ___________________________________ 685
 Sobrevida e complicações em idosos com doenças neurológicas  
 em nutrição enteral ______________________________________________________ 691
 Inﬂiximab reduces cardiac output in rheumatoid arthritis patients  
 without heart failure ______________________________________________________ 698
 Análise dos resultados maternos e fetais dos procedimentos invasivos  
 genéticos fetais: um estudo exploratório em Hospital Universitário _______________ 703
 Frequência dos tipos de cefaleia no centro de atendimento terciário do  
 Hospital das Clínicas da Universidade Federal de Minas Gerais __________________ 709
ARTIGO DE REVISÃO ______________ Inﬂuência das variáveis nutricionais e da obesidade sobre a saúde e o metabolismo __ 714
EDITORIAL
Conclusão: como exibir a cereja do bolo 633
PONTO DE VISTA
Os paradoxos da medicina contemporânea 634
IMAGEM EM MEDICINA
Obstrução duodenal maligna: tratamento 
endoscópico paliativo utilizando prótese  
metálica autoexpansível 636
Gossypiboma 638
DIRETRIZES EM FOCO
Hérnia de disco cervical no adulto:  
tratamento cirúrgico 639
ACREDITAÇÃO
Atualização em perda auditiva:  
diagnóstico radiológico 644
SEÇÕES ____________________________  
www.ramb.org.br
Revista da
ASSOCIAÇÃO MÉDICA BRASILEIRA
REV ASSOC MED BRAS. 2013;59(5):467-474
Original article 
Laser therapy in oral mucositis control: 
a meta-analysisq
André Luiz Peixoto Figueiredoa, Liliane Linsa,b,*,
Ana Carolina Cattonya, Antônio Fernando Pereira Falcãoc
a Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil
b Medicine School of Bahia, UFBA, Salvador, BA, Brazil
c Faculty of Dentistry, Universidade Federal da Bahia (UFBA), Salvador, BA, Brazil
ARTICLE INFO
Article history:
Received 25 August 2012
Accepted 19 August 2013
Keywords:
Laser therapy
Oral mucositis
Prevention
Meta-analysis
q Study conducted at the Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil.
*  Corresponding author.
E-mail: lilianelinskusterer@bahiana.edu.br; liliane.lins@ufba.br (L. Lins).
A B S T R A C T
Objective: To perform a systematic review and meta-analysis of the effectiveness of laser 
therapy (LT) in the prevention of oral mucositis (OM) in patients undergoing oncotherapy.
Methods: A search was conducted in the MEDLINE, LILACS, and Cochrane databases using the 
keywords “laser therapy” and “oral mucositis” in order to perform this systematic review and 
meta-analysis. The case-control studies included were submitted to odds ratio (OR) analysis, 
whose cut-off for statistic calculation was OM grade ≥ 3. Calculations were performed with 
the BioEstat program, release 5.0, using DerSimonian-Laird’s random effects statistical 
analysis. 
Results: In this systematic review, twelve studies were included; the meta-analysis of seven 
of them demonstrated that LT in patients undergoing oncotherapy is approximately 10 times 
more effective in the prevention of OM grade ≥ 3 than in patients without laser treatment 
(OR: 9.5281; 95% CI: 1.447-52.0354; p = 0.0093).
Conclusion: The data demonstrated the significant prophylactic effect of OM grade  ≥  3  in 
patients undergoing LT. Further studies, with larger sample sizes, are needed for better 
evaluation of LT’s prophylactic effect on OM grade ≥ 3.
© 2012 Elsevier Editora Ltda. 
Laser terapia no controle da mucosite oral: um estudo de metanálise
R E S U M O
Objetivo: Realizar uma metanálise da eficácia da laser terapia (LT) na prevenção da mucosite 
oral (MO) em pacientes submetidos à oncoterapia. 
Métodos: Foi realizada uma busca nas bases de dados MEDLINE, LILACS e Cochrane, utilizando 
as palavras-chave “laser therapy” e “oral mucositis”. Os estudos de caso-controle incluídos 
foram submetidos à análise do odds ratio (OR), cujo ponto de corte para a estatística foi MO 
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grau ≥  3. Os cálculos foram realizados com o programa BioEstat 5.0, utilizando a análise 
estatística de Efeito Aleatório de DerSimonian-Laird. 
Resultados: Doze estudos foram incluídos na revisão sistemática. A metanálise de sete deles 
evidenciou que a LT em pacientes submetidos à oncoterapia é aproximadamente 10 vezes 
mais eficaz na prevenção de MO grau ≥ 3 do que em pacientes sem o tratamento com laser 
(OR: 9,5281; intervalo de confiança de 95% 1,447-52,0354, p = 0,0093). 
Conclusão: Esses dados demonstraram efeito profilático significativo de MO grau  ≥  3  nos 
pacientes submetidos à LT. Estudos com maior tamanho amostral são necessários para 
melhor avaliação do efeito profilático de MO grau ≥ 3 por LT.
© 2012 Elsevier Editora Ltda. 
Introduction
Many patients with cancer are submitted to an initial therapy 
by radiotherapy (RT), surgery and chemotherapy (CT). RT is 
usually the treatment of choice in cases involving the head and 
neck, where the irradiation field involves the oral mucosa and 
salivary glands.1 Alone or combined with CT, RT has a good 
clinical response in the treatment of stage I and stage II cancer. 
However, cancer therapy is closely related to the location of the 
tumor, its staging, its histological type, as well as the patient’s 
status.2
Additionally, in cases of malignant and non-malignant 
hematological diseases, severe immunodeficiency, and bone 
marrow aplasia, one of the recommended treatments is 
hematopoietic stem cell transplantation3 (HSCT). Therefore, 
bone marrow transplantations require the continuous use of 
a conditioning regimen responsible for myeloablation, in order 
to create space in the recipient’s bone marrow.4 Therefore, 
immunosuppression and destruction of neoplastic cells 
are other effects of high doses of CT drugs, whether or not 
combined with RT.
Mucosal inflammation is a frequent acute complication 
in patients with malignancies undergoing oncotherapy. 
Among patients with head and neck cancer treated with 
RT, 90% to 97% have some degree of oral mucositis5 (OM). 
Literature indicates that the incidence of OM, in any degree, 
associated with oncotherapy for HSCT varies between 76.3% 
and 89%.6 However, some risk factors appear to be implicated 
in the pathogenesis of OM, such as the location of the radiation 
field, preexisting dental disease, poor oral hygiene, low saliva 
production, compromised immune function, and focus of local 
infection.7,8
The toxicity produced by the treatment causes alterations 
that manifest as mucositis, in light of its action on cells with 
high mitotic activity.9 Thus, there is an intense mucosal 
involvement, with a decrease in the capacity to overcome the 
natural exfoliation process, and consequent inflammation and 
edema.
Associated with a directly harmful effect on the mucous 
cells, pro-inflammatory cytokines play a role in the worsening 
of initial mucosal lesions. Tumor necrosis factor-a (TNF-a) 
and interleukin-1b, interleukin-11, and interleukin-6 appear 
to play an important role in tissue damage associated with 
oncotherapy.10 According to the literature,11 there are four 
stages in the mucosal lesion process: (1) white patches, with 
intra- and extracellular edema; (2) appearance of erythematous 
areas in mucosa, in addition to dysphagia; (3) raised areas of 
the superficial layers of the mucosa, with reddish borders 
and re-covered by serofibrinous pseudomembrane, (4) when 
erythematous areas or areas with pseudomembrane are not 
re-covered in time, there is a loss of mucous lining, increase 
of the pain, and fever can occur, and oncotherapy interruption 
becomes necessary. 
The inflammatory picture causes pain and discomfort, 
with impairment of speech, deglutition, and feeding, and 
ulcerating lesions can lead to dehydration and poor nutrition. 
Furthermore, the ulcerations bring a high risk of microbial 
invasion, causing predisposition to local or systemic 
infections.12 The increased severity of OM may cause fever, 
infection risk, need for total parenteral nutrition, need 
for intravenous analgesics, and mortality during the first 
100 days.13
The severity of OM is commonly assessed by the Oral 
Toxicity Scale, a graduated scale established by the World 
Health Organization (WHO). This scale contains criteria such 
as the presence of erythema and ulceration, local pain, and 
deglutition capacity. When the score is 0 no abnormality has 
been detected; the presence of erythema without need for 
treatment characterizes a score of 1; a score of 2 indicates the 
presence of painful symptoms with no need for analgesics, 
with difficulty in feeding; a score of 3  indicates painful 
ulceration requiring the use of analgesics and preventing 
feeding; finally, a score of 4  indicates necrosis requiring 
parenteral nutrition.14
Another form of assessment that can be used to evaluate 
OM is the Toxicity Criteria recommended by the National 
Cancer Institute (NCI), which establishes grade 0 in the absence 
of OM; grade 1 when there are painless ulcers, erythema, or 
mild pain in the absence of ulcers; grade 2 in the presence of 
painful erythema, edema, or ulcers, but feeding or swallowing 
is possible; grade 3 in the presence of painful erythema, edema, 
or ulcers when there is need of parenteral nutrition; grade 4, in 
case of severe ulcerations or need for parenteral nutrition or 
prophylactic intubation; and grade 5, in case of death-related 
toxicity.13 Among other scales used to classify the severity of 
OM, the Radiation Therapy Oncology Group (RTOG) scale must 
be cited, which also evaluates, in general, oral toxicity derived 
from the cancer treatment used.13 The Oral Mucositis Index 
(OMI) is another tool used in the classification of OM.15 In 1996, 
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Tardieu et al. created the Quantitative Scale of Oral Mucositis 
by HSCT, used in some articles to assess OM.16
Despite a considerable range of studies performed in the 
last ten years regarding the prevention of OM due to cancer 
treatment, preventive measures have yet to be established for 
mucosal inflammation due to oncotherapy.17 The literature 
has recorded the use of over 20 preventive measures for oral 
mucositis caused by oncotherapy,18 of which the following 
may be cited: cryotherapy, chlorhexidine gluconate, oral 
hygiene, glutamine, benzydamine, sucralfate, vitamin E, and 
rinsing the mouth with salt and soda.19,20 However, there is 
a scarcity of scientific evidence regarding the clinical usage 
of agents such as benzydamine and cryotherapy.20 Currently, 
OM prevention is predominantly based on palliative care 
(oral rinses, anti-inflammatory drugs, and oral hygiene) and 
prevention of secondary infections. 
Some studies, however, suggest other prophylactic 
measures, acting on the biological mechanisms involved in 
each phase of OM, such as the use of low-intensity laser.12
Laser therapy (LT) is known to stimulate biological 
effects, such as elimination of pain and inflammatory 
modulation. The ability to modulate a variety of metabolic 
events through photophysical and biochemical processes 
explains the effects of this therapy.21,22 The laser energy is 
absorbed only by a thin layer of surrounding tissue beyond 
the point affected by the radiation. For this reason, the use of 
lasers with low penetration power is currently recommended, 
with wave lengths of 640 nm to 940 nm, which should be 
used immediately after the lesion occurs.23 For comparison, 
the visible red light-emitting diode has less penetration 
power, being more suitable for tissue repair, while the 
diode with longer wavelength, which emits infrared laser, 
has a greater capacity to penetrate, being more indicated 
for analgesia. Low-intensity lasers increase cell metabolism 
by stimulating mitochondrial activity,24 acting as analgesic, 
anti-inflammatory, and reparative agents in mucosal 
lesions.25 They cause several biological events, such as 
epithelial and fibroblast proliferation as well as maturation, 
transportation, and transformation of fibroblasts into 
myofibroblasts.26
There are also cell and vascular alterations that depend, 
among other factors, on the laser wavelength. These 
include production of collagen, elastin, and proteoglycans; 
revascularization; wound contraction; increased phagocytosis 
by macrophages; and increased proliferation and activation 
of lymphocytes and higher tensile strength, accelerating the 
healing process. 
Helium-neon (He-Ne) and gallium-aluminun-arsenic 
(Ga-Al-As) lasers have shown good results when used in 
cases of OM caused by oncotherapy. Although studies have 
suggested a significant role of LT in the treatment of OM due 
to oncotherapy,27 further studies are necessary to assess 
the efficacy of prophylactic LT use at low doses in severe 
inflammation of the oral mucosa. 
Considering the need for further studies on the use of LT 
in patients with OM caused by oncotherapy, this study aimed 
to perform a systematic review and meta-analysis of the 
effectiveness of LT in preventing the development of OM ≥ 3 
in patients undergoing cancer treatments.
Methods
Search strategy
From January to February of 2012, a search was performed 
in the LILACS, MEDLINE, and Cochrane electronic databases, 
with no restriction regarding the year of publication of the 
articles. The following key words used were in all databases: 
“laser therapy” and “oral mucositis”, aiming at standardizing 
the research. Initially, three researchers analyzed the titles 
and abstracts of studies listed in the databases. Then, the 
studies selected after evaluation of their abstracts were further 
analyzed by the researchers. Based on this assessment, the 
studies were submitted to the inclusion and exclusion criteria 
for the meta-analysis. 
Criteria for inclusion and exclusion of studies
Considering the expected statistical analysis, studies were 
included when (1) the patients had a diagnosis of OM caused 
by oncotherapy, during or after treatment; (2) the treatment 
of the oral mucosa was performed with low-intensity laser, 
whose wavelength was set between 632 and 1,064 nm; and 
(3) the study design consisted of a randomized trial with a 
control group. 
Data collection and study quality
The relevant data for the study were extracted by three 
researchers using a standardized form. The form was created 
based on the identification of the most relevant data for the 
study, containing information about the authors, year of 
publication, country of origin, and study design.
The data on the population of each study were also 
analyzed: sample, type of cancer, type of oncotherapy, gender, 
age of patients and controls, as well as the type of treatment 
used for the control group. The wavelength applied through 
the LT (in nm), type of laser used, laser power (in mW), dose (in 
J/cm2), irradiation time (in seconds), and number of sessions 
per week were also included in the standardization. To assess 
the methodological quality, the studies included in the analysis 
were analyzed according to the Jadad scale.28
Statistical analysis
For the analyzed data, a meta-analysis was performed using 
BioEstat release 5.0, using DerSimonian-Laird’s random effect 
analysis method, considering the heterogeneity of the studies. 
The odds ratio (OR) and 95% confidence interval (95% CI) 
were calculated for each study individually and then for the 
combination of the selected studies. Only p-values < 0.05 were 
considered significant. To assess the effectiveness of LT 
prophylactic capacity, the presence of OM ≥ 3 at the end of LT 
was used as cutoff in all of the scales; this is the grade of OM 
in which painful ulcerations are observed, requiring the use of 
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analgesics and preventing feeding.11 The determination of this 
criterion is justified by the painful symptoms, food restriction, 
and discontinuation of treatment in the presence of severe 
inflammation of the mucosa.
Results
A literature search disclosed 149 studies with keywords “oral 
mucositis” and “laser therapy”. Forty-one studies considered 
potentially relevant were selected for detailed evaluation of 
the inclusion and exclusion criteria. Of these, five were review 
articles, four were case studies, four addressed LT only as a 
therapeutic measure, four did not have a control group, and 
two did not include oncotherapy in the analysis. In addition, 
two studies did not address LT and two were article comments 
and were excluded. 
The final sample consisted of 12 prospective randomized 
studies, published between 1997 and 2011, with a total sample 
of 527 patients. The total number of patients undergoing LT 
included in the 12 studies was 276, whereas the control group 
consisted of 251 patients. Among the patients in the sample, 
the overall frequency of head and neck cancer was 47%, 
whereas 53% of the patients in the sample were treated for 
hematological malignancies (Table 1). 
Study description
Of the articles included, two studies29,30 were performed 
in France, one in India,31 and nine studies were conduc-
ted in Brazil.32-40 All studies included in the analysis were 
case-control studies, and three of them31,34,39 reported pros-
pec tive follow-up. Among the selected studies, it is unclear 
whether there were methodological differences in patient 
assessment, with varying inclusion criteria in the sample. In 
seven studies,31,32,34-37,40 at the beginning of the experiments, 
the group undergoing LT and the control group did not present 
OM. Four studies29,30,33,38 did not report the status of the oral 
mucosa at the beginning of their study. 
Regarding the type of oncotherapy, in three studies30,31,36 
patients were treated with RT alone, while in six 
others29,33,34,36,37,40 CT was the only anticancer treatment. 
One study subdivided the sample submitted to oncotherapy 
into a group treated with CT for HSCT, and a group where CT 
was the conventional treatment of solid tumors.32 Another 
article described the treatment of their patients restrictively 
with combined CT and RT.38 Similarly, other authors39 used 
four types of combinations of treatments that included 
surgery, CT, and RT.
Regarding demographic data, the group of patients 
submitted to LT consisted mostly of males.30,32,35,37-40 The 
mean age of patients undergoing LT was ≥ 50 years in four 
studies30,31,38,39 and among controls, in four as well.30,31,38,39 
Two of the studies included in the analysis consisted of 
pediatric patients only.32,34
The WHO scale was used in four studies,30,37,39,40 whereas 
the NCI oral toxicity scale was used in three.32,34,38 One study33 
assessed OM through the OMI15; however, this same study 
established a degree of comparison between the OMI and 
the scale recommended by WHO; thus, the numbers based 
on the latter were used by the present study. One study39 
used the WHO and NCI scales, finding similar results, and the 
NCI classification showed a higher percentage of grade 3 OM 
than the WHO scale. Two studies29,36 evaluated OM using the 
Tardieu classification.16
The measure used for OM prevention in the control groups 
showed a significant variation. Eight studies30,33-36,38-40 used 
placebo laser, and one study39 used in the control group the 
same laser as in the study group, but with lower potency and 
N Author Year Country Study design Sample Neoplasia Oncotherapy
 1 Cowen et al.29 1997 France Prospective 30 ALL, AML, MM, NHL CT
 2 Bensadoun et al.30 1999 France Prospective 30 Head and neck RT
 3 Arun-Maiya et al.31 2006 India Prospective 50 Head and neck RT
 4 Cruz et al.32 2007 Brazil Prospective 59 Leukemia/Lymphoma: 35 CT
Solid tumors: 25
 5 Schubert et al.33 2007 Brazil Prospective 70 Leukemia/Lymphoma CT
 6 Abramoff et al.34 2008 Brazil Prospective 22 Osteosarcoma CT
ALL
 7 Kuhn et al.35 2008 Brazil Prospective 23 Head and neck RT
 8 Chor et al.36 2009 Brazil Prospective 34 HSCT CT
 9 Khouri et al.37 2009 Brazil Prospective 22 ALL, AML, CML, MDS, SAA CT
10 Gouvêa de Lima et al.38 2010 Brazil Prospective 75 Head and neck CT + RT
11 Carvalho et al.39 2011 Brazil Prospective 70 Head and neck Sur + CT: 26
Sur + RT + CT: 27
RT + CT: 13
RT: 4
12 Silva et al.40 2011 Brazil Prospective 42 Leukemia/Lymphoma CT
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CT, chemotherapy; HSCT hematopoietic 
stem cell transplant; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; RT, radiotherapy; SAA, severe 
aplastic anemia; Sur, surgery.
Table 1 – Preliminary data from the included studies.
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dose. Conversely, the other placebo-controlled studies used 
the same laser device as the group submitted to LT, but the 
device was turned off during the use in the control group. One 
study31 used a combination of oral analgesics, anesthetics, 0.9% 
saline solution, and antiseptics as prophylactic tools in the 
control group. Information regarding the type of prophylactic 
measure chosen for the control group, the type of scale used 
to assess OM, and the cutoff used in the present study are 
shown in Table 2. 
Regarding LT, five studies33-36,38 used only the Ga-As-Al 
laser, four studies29-31,39 used the He-Ne laser, one study40 used 
only indium-gallium-aluminum-phosphorus (In-Ga-Al-P) 
laser. and another37 used two types of lasers on alternate 
days, one emitting red visible light (660 nm [In-Ga-Al-P]) 
and another infrared (780 nm [–Ga-Al-As]) on alternate days. 
One article32 did not report the type of laser used in patients 
undergoing CT. Only one study33  subdivided the group 
submitted to LT with Ga-Al-As into two smaller groups: a 
subgroup submitted to a wavelength of 650 nm, with a 2 J dose 
and 40 mW power, and another submitted to 780 nm, with a 
2 J dose and 60 mW power. 
Four of the 12 studies did not observe losses in their 
samples,29,30,31,34 whereas three did not describe losses during 
the experiments.36,37,38 Two patients in one study33 died from 
complications related to OM. In one study,39 eight patients 
were excluded from the sample. Another study32 started with 
a sample of 62 patients, two of whom were excluded for not 
following the protocol established by the authors. Furthermore, 
at the end of the experiments, the researchers32 evaluated only 
59 of the 60 patients included, providing no justification for 
the procedure. One study intended to evaluate 30 patients, but 
only 23 completed the treatment with LT. Moreover, without 
giving any justification, the authors35 did not include patient 
number 12 in the sample reported in the publication. Another 
study40 intended to evaluate 56 patients; however, 14 subjects 
were excluded for not meeting the criteria established for 
inclusion in the experiment. 
Study quality
Study assessment were performed according to the Jadad 
scale,28 showing similar methodology validations. Eight studies 
were considered as high quality,29,30,32-35,38,39  three were 
classified as moderate quality,31,37,40 and one as low quality.36
Meta-analysis
Only seven of the 12 studies included in this review provided 
sufficient data to classify successes (OM grade < 3) and failures 
(OM grade ≥ 3). The meta-analysis was performed based on 
the seven articles listed,31,32,34,35,37,38,40 with a total sample 
of 293 patients. The combined OR of the studies was 9.5, 
with p = 0.0093, contained in a 95% CI 1.447-52.0354, whose 
lower limit was > 1. The results rejected the null hypothesis 
and demonstrated that the effectiveness in preventing OM 
grade ≥ 3 by LT is approximately 10 times (OR: 9.5) higher than 
in those individuals not treated with LT (p = 0.0093). 
The forest plot chart shows the analysis of the LT effect on 
the prevention of OM grade ≥ 3, compared with no treatment. 
Results to the right show the values  of studies favorable to LT; 
N Author OM scale OM prevention control Laser therapy Control 
    G < 3 G ≥ 3  G < 3 G ≥ 3
 1 Cowen et al.a,b Tardieu — — — — —
 2 Bensadoun et al.a WHO Placebo — — — —
 3 Arun-Maiya et al. WHO Oral analgesics  25 0  0  25
Anesthetics
0.9% saline solution
Antiseptics
 4 Cruz et al.b NCI —  26 2 28   3
 5 Schubert et al.x OMI Placebo — — — —
 6 Abramoff et al. NCI Placebo  11 0 10   1
 7 Kuhn et al. WHO Placebo  11 0  5   7
 8 Chor et al.c Tardieu Placebo — — — —
 9 Khouri et al. WHO Mouthwash  12 0  5   5
10 Gouvêa de Lima et al. NCI Placebo  29 8 29   9
11 Carvalho et al.a WHO/NCI Placebo — — — —
12 Silva et al.b WHO Mouthwash  21 0 15   6
Combined total   135 2  92 107
G < 3, OM grade < 3; G ≥ 3, OM grade ≥ 3; Tardieu, Quantitative scale of oral mucositis associated with autologous bone marrow transplantation 
(Tardieu et al., 1996), daily index of mucositis (DIM); WHO, Oral Toxicity Scale of the World Health Organization (1979); 
NCI, Toxicity Scale of the National Cancer Institute; RTOG, Oral Toxicity Scale of the Radiation Therapy Oncology Group; OMI, Oral Mucositis 
Index.
a Disclosed only the means of OM grades at the end of the study. 
b There was no treatment for the control group.
c Disclosed only the p-value in results.
Table 2 – Results of included studies.
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the combined effect was represented by the diamond shape 
(Fig. 1). The heterogeneity test applied in the DerSimonian-Lair 
analysis was significant (p = 0.0018), statistically demonstrating 
the effect of LT on the prevention of OM grade ≥  3. The 
Chi-squared analysis of the heterogeneity of the seven 
studies included in the meta-analysis31,32,34,35,37,38,40 showed 
p = 0.0006, with six degrees of freedom, which was significant, 
indicating the existence of heterogeneity among the studies 
and justifying the choice of the DerSimonian-Laird test.
All studies included in this meta-analysis investigated the 
possibility of adverse effects associated with LT. None of the 
included studies demonstrated any side effects resulting from 
their experiments.29-40
Discussion
The use of low-intensity laser in the oral cavity is capable 
of preventing the occurrence of OM grade ≥ 3  in patients 
undergoing oncotherapy, and, in individuals undergoing LT, 
this prophylaxis is approximately nine times more effective 
than the absence of LT in the control group (OR: 9.52). These 
results differ from some literature data; for instance, among 
the 12 studies included in this study, three did not observe, in 
a general manner, the effectiveness of LT in OM prevention in 
patients undergoing anticancer therapy.32,36,38
After a systematic review aiming to combine studies in 
a meta-analysis, it was observed that the studies were not 
identical regarding the effect of prevention of OM grade ≥ 3 by 
LT. Consequently, the differences were investigated and 
the alternative found for the heterogeneity was to use 
DerSimonian-Laird’s random effect analysis. This test 
considers not only the existence of the variation within each 
study included, but also the differences among the studies. 
It can be inferred that the random effects model does not 
consider the studies as identical, but admits that a probability 
distribution establishes an association between the studies. 
Through sensitivity analysis, the heterogeneity among the 
meta-analysis studies was demonstrated, which can be 
attributed to methodological differences and to the different 
prophylactic measures used in the control group. Thus, the 
present study sought to reduce biases as much as possible, 
which could affect result interpretation and quality, using the 
criteria discussed below. 
The literature review was broad and comprehensive, 
seeking to reduce publication bias by not restricting the 
language, by including studies published in scientific journals 
with lower scientific visibility, and by including studies 
with negative results on the efficacy of LT in preventing OM 
grade ≥ 3 in patients undergoing oncotherapy. The selection of 
studies, which was performed in accordance with the criteria 
of study design (case-control), of OM diagnosis, and LT as the 
only way of preventing oncotherapy-induced OM grade ≥ 3, 
sought to reduce the heterogeneity of the included studies, 
while encompassing the clinical situation proposed by the 
project question (“iss low-intensity LT effective in controlling 
oncotherapy-induced OM grade ≥ 3?”).
The use of a standardized form, created at a meeting 
prior to the data collection, in addition to the participation 
of three researchers to extract the data, contributed to bias 
reduction at the data collection stage. After the stages of 
searching and collecting data from the studies, seven of the 
12 articles included in the systematic review were selected. 
The sensitivity analysis, through the chi-squared test, 
demonstrated the presence of heterogeneity. Thus, taking 
into account the clinical and methodological differences of 
the included studies,DerSimonian-Laird’s random effect test 
was chosen to calculate the combined OR, as suggested by the 
literature.41
Research has13 evidenced that an increase in OM severity 
can present systemically as fever, risk of infection, total 
parenteral nutrition dependence, intravenous analgesic 
use, and mortality during the first 100 days. Therefore, the 
confirmation of the prophylactic effects of LT corroborating 
the large number of studies conducted in this area in the 
past 20 years would be a method to reduce the limitation to 
Fig. 1 – Forest plot chart of the studies included in the random effect analysis and combined odds ratio and odds ratio of the 
included studies.
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oncotherapy. Literature reports42,43 that the tumor site can 
be better controlled with the use of LT, and there may be 
increased survival in cancer patients, as well as improvement 
in their quality of life.
Regarding the remission of painful symptoms, only two 
studies32,38 included in the meta-analysis showed no evidence 
of pain relief with the use of LT. It should be noted that 
one of these studies38 reported the interruption of treatment 
of oncological patients in the placebo group as a possible 
limitation of the study related to its findings. The other 
studies31,34,35,37,40 showed evidence of decrease in painful 
symptoms, as well as control in the progression of OM. 
Recently, a meta-analysis44 was performed on the effects 
of low-intensity LT in oncotherapy-induced OM, whose 
combined OR results were similar to those found in the 
present study (p < 0.0001, and combined chi-squared analysis 
of 32.93). The inclusion criteria used in that meta-analysis, 
however, were very comprehensive, which probably resulted 
in its greater heterogeneity. Another recent meta-analysis45 
included studies that assessed the effect of LT, sucralfate, 
and benzy damine hydrochloride in the treatment of OM in 
patients undergoing oncotherapy, including CT, RT, or both 
procedures. Of the therapies studied, only LT appeared to 
reduce severe mucositis. It should be noted that, as in the 
present study, the meta-analyses on LT included different 
samples concerning age, different modalities of cancer 
treatment, different laser characteristics, therapeutic dose, 
and mucositis grade scales. 
The current study did not consider demographic factors 
when analyzing the effectiveness of LT in preventing OM 
grade ≥ 3, as they do not appear to influence the final result. 
The present systematic review with meta-analysis showed 
evidence of moderate to high efficacy of low-intensity LT in 
the prophylaxis of oncotherapy-induced OM. One limitation to 
the present study study may be the lack of studies exclusively 
on prevention of oncotherapy-induced OM by low-intensity 
LT. In general, the scientific studies were methodologically 
acceptable, but heterogeneous prophylactic procedures, as well 
as doses, may have caused the conflict. Furthermore, the small 
number of patients reported in the literature accounts for an 
important limitation imposed on the present study. 
Conclusion
According to the results obtained from the statistical analysis 
shown in this meta-analysis, it is clear that LT, when applied to 
patients undergoing oncotherapy, is effective in controlling OM 
grade ≥ 3. Studies have demonstrated the importance of severe 
OM prevention during the course of oncotherapy, stressing, in 
practice, the limitations imposed by OM grade ≥ 3, which may 
even lead to treatment discontinuation. 
Regarding the use of low-intensity laser, factors such as 
wavelength, dose, duration of irradiation, power, and number 
of sessions have remarkable influence on the outcome of 
prevention, which may explain the varied results among 
studies and their heterogeneity. 
Although a large number of studies have been performed 
on OM prevention in cancer patients, there is still little 
published scientific evidence capable of establishing the use 
of LT in clinical practice on a large scale. For a more accurate 
evaluation of the prophylactic effect of OM grade ≥ 3 by LT in 
patients undergoing some kind of oncotherapy, further studies 
are needed, with larger sample sizes.
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